In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

2012 ◽  
Vol 92 (3) ◽  
pp. 366-375 ◽  
Author(s):  
H de Jonge ◽  
H de Loor ◽  
K Verbeke ◽  
Y Vanrenterghem ◽  
D R Kuypers
Keyword(s):  
Renal Transplant ◽  
Cyp3a4 Activity ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Renal Transplant Patients ◽  
Tacrolimus Dose

scholarly journals Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Oncotarget ◽  
2017 ◽  
Vol 8 (46) ◽  
pp. 81285-81294 ◽  
Author(s):  
Lihui Qu ◽  
Yingying Lu ◽  
Meike Ying ◽  
Bingjue Li ◽  
Chunhua Weng ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Dose Requirement ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Renal Transplant Patients ◽  
Tacrolimus Dose

CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients

2013 ◽  
Vol 94 (2) ◽  
pp. 201-202 ◽  
Author(s):  
A B Santoro ◽  
C J Struchiner ◽  
C R Felipe ◽  
H Tedesco-Silva ◽  
J O Medina-Pestana ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Renal Transplant Patients ◽  
Tacrolimus Dose

scholarly journals Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Oncotarget ◽  
2020 ◽  
Vol 11 (16) ◽  
pp. 1474-1477
Author(s):  
Lihui Qu ◽  
Yingying Lu ◽  
Meike Ying ◽  
Bingjue Li ◽  
Chunhua Weng ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Dose Requirement ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Renal Transplant Patients ◽  
Tacrolimus Dose

scholarly journals Development Of De Novo Donor-Specific HLA Antibodies and ABMR in Renal Transplant Patients Depends on CYP3A5 Genotype

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Justa Friebus-Kardash ◽  
Ejona Nela ◽  
Birte Möhlendick ◽  
Andreas Kribben ◽  
Winfried Siffert ◽  
...  
Keyword(s):  
Renal Transplant ◽  
De Novo ◽  
Hla Antibodies ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Renal Transplant Patients

scholarly journals CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Yilei Yang ◽  
Xin Huang ◽  
Yinping Shi ◽  
Rui Yang ◽  
Haiyan Shi ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Renal Transplant ◽  
High Performance ◽  
Therapeutic Drug ◽  
Transplant Patients ◽  
Cyp3a5 Genotype ◽  
Group I ◽  
Trough Concentrations ◽  
Renal Transplant Patients ◽  
Group Ii

Purpose: The drug-drug interactions (DDIs) of tacrolimus greatly contributed to pharmacokinetic variability. Nifedipine, frequently prescribed for hypertension, is a competitive CYP3A5 inhibitor which can inhibit tacrolimus metabolism. The objective of this study was to investigate whether CYP3A5 genotype could influence tacrolimus-nifedipine DDI in Chinese renal transplant patients.Method: All renal transplant patients were divided into CYP3A5*3/*3 homozygotes (group I) and CYP3A5*1 allele carriers (CYP3A5*1/*1 + CYP3A5*1/*3) (group II). Each group was subdivided into patients taking tacrolimus co-administered with nifedipine (CONF) and that administrated with tacrolimus alone (Controls). Tacrolimus trough concentrations (C0) were measured using high performance liquid chromatography. A retrospective analysis compared tacrolimus dose (D)-corrected trough concentrations (C0) (C0/D) between CONF and Controls in group I and II, respectively. At the same time, a multivariate line regression analysis was made to evaluate the effect of variates on C0/D.Results: In this study, a significant DDI between tacrolimus and nifedipine with respect to the CYP3A5*3 polymorphism was confirmed. In group I (n = 43), the C0/D of CONF was significantly higher than in Controls [225.2 ± 66.3 vs. 155.1 ± 34.6 ng/ml/(mg/kg); p = 0.002]. However, this difference was not detected in group II (n = 27) (p = 0.216). The co-administrated nifedipine and CYP3A5*3/*3 homozygotes significantly increased tacrolimus concentrations in multivariate line regression analysis.Discussion: A CYP3A5 genotype-dependent DDI was found between tacrolimus and nifedipine. Therefore, personalized therapy accounting for CYP3A5 genotype detection as well as therapeutic drug monitoring are necessary for renal transplant patients when treating with tacrolimus and nifedipine.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

2004 ◽  
Vol 14 (3) ◽  
pp. 147-154 ◽  
Author(s):  
Vincent Haufroid ◽  
Michel Mourad ◽  
Val??rie Van Kerckhove ◽  
Jeremie Wawrzyniak ◽  
Martine De Meyer ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Blood Levels ◽  
Transplant Patients ◽  
Trough Blood ◽  
Renal Transplant Patients ◽  
Tacrolimus Dose
Sign in / Sign up

Export Citation Format

Share Document